Compare HMC & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMC | ONC |
|---|---|---|
| Founded | 1946 | 2010 |
| Country | Japan | Switzerland |
| Employees | N/A | 12000 |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.2B | 40.6B |
| IPO Year | 2002 | 2015 |
| Metric | HMC | ONC |
|---|---|---|
| Price | $31.58 | $347.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | N/A | ★ $385.10 |
| AVG Volume (30 Days) | ★ 1.1M | 392.3K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.45% | N/A |
| EPS Growth | N/A | ★ 140.43 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $238,387,000.00 |
| Revenue This Year | N/A | $723.76 |
| Revenue Next Year | $4.36 | $15.04 |
| P/E Ratio | ★ $40.40 | $1,148.32 |
| Revenue Growth | N/A | ★ 22179.16 |
| 52 Week Low | $23.25 | $253.95 |
| 52 Week High | $34.89 | $385.22 |
| Indicator | HMC | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 65.48 | 64.05 |
| Support Level | $29.29 | $325.47 |
| Resistance Level | $31.53 | $353.10 |
| Average True Range (ATR) | 0.49 | 7.80 |
| MACD | 0.04 | 1.70 |
| Stochastic Oscillator | 80.48 | 65.02 |
Incorporated in 1948, Honda Motor was originally a motorcycle manufacturer. Today, the firm makes automobiles, motorcycles, and power products such as boat engines, generators, and lawnmowers. Including joint ventures, Honda sold 3.4 million light vehicles and 22.1 million motorcycles in fiscal 2026, and consolidated sales were JPY 21.8 trillion. Automobiles constitute 64% of revenue and motorcycles 18%, with the rest split between power products and financial services. Honda also makes robots and private jets.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.